Roge Karma

Roge Karma is the founder of BridgeUSA, which empowers students on over 30 college campuses to create spaces where individuals from across the political spectrum can engage in responsible discourse. 

Recent Articles

Seizing the Family and Community Values Narrative

Americans are concerned about health care, education, worker rights, and climate change. Democrats should own these issues, go beyond bashing billionaires, and move toward a more comprehensive agenda for 2020. 

The future of the Republican Party seems grim. For decades, Republicans have portrayed themselves as the party of families, dignified work, local communities and human decency. But in the wake of a Republican president who consistently affronts human decency, grew rich on inherited wealth and cheating the system, and treats executive authority like a personal playground, there has never been a better opportunity for the Democratic Party to win back the family and community values narrative. Yet, doing so will require more than calling out Republicans as hypocrites and bashing billionaires. In the last year, progressive candidates have put forward a slew of bold, innovative policy ideas from the Green New Deal to universal basic income and worker co-determination. However, these ideas are only vaguely connected to one another, let alone a broader vision of society. It is obvious what the Democrats stand against— Republican politicians, the billionaire class and corporations...

Alexandria Ocasio-Cortez and the Myth of American Innovation

The intrepid New Yorker pulls back the curtain on how private companies profit from taxpayer-funded research.

Over the last decade, pharmaceutical companies have spent close to $2.5 billion lobbying members of congress, including hundreds of millions of dollars to help shape and promote the passage of Obamacare (which resulted in around $35 billion in additional profits for the industry). For years, politicians from across the political spectrum have given Big Pharma a pass . So, when this clip surfaced of an exchange between Congresswoman Alexandria Ocasio-Cortez of New York and Aaron Kesselheim of Harvard during congressional hearings on the drug industry earlier this year, it was an eye-opener. With just two questions, Ocasio-Cortez punctured a gaping hole in the myth of pharmaceutical innovation: Ocasio-Cortez: “Would it be correct, Dr. Kesselheim, to characterize the NIH [National Institutes of Health] money that is being used in development and research as an early investment? The public is acting as an early investor in the production of these drugs. Is the public receiving any...